TY - JOUR
T1 - European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients
AU - Nyssen, Olga P.
AU - Bordin, Dmitry
AU - Tepes, Bojan
AU - Pérez-Aisa, Ángeles
AU - Vaira, Dino
AU - Caldas, Maria
AU - Bujanda, Luis
AU - Castro-Fernandez, Manuel
AU - Lerang, Frode
AU - Leja, Marcis
AU - Rodrigo, Luís
AU - Rokkas, Theodore
AU - Kupcinskas, Limas
AU - Pérez-Lasala, Jorge
AU - Jonaitis, Laimas
AU - Shvets, Oleg
AU - Gasbarrini, Antonio
AU - Simsek, Halis
AU - Axon, Anthony T R
AU - Buzás, György
AU - Machado, Jose Carlos
AU - Niv, Yaron
AU - Boyanova, Lyudmila
AU - Goldis, Adrian
AU - Lamy, Vincent
AU - Tonkic, Ante
AU - Przytulski, Krzysztof
AU - Beglinger, Christoph
AU - Venerito, Marino
AU - Bytzer, Peter
AU - Capelle, Lisette
AU - Milosavljević, Tomica
AU - Milivojevic, Vladimir
AU - Veijola, Lea
AU - Molina-Infante, Javier
AU - Vologzhanina, Liudmila
AU - Fadeenko, Galina
AU - Ariño, Ines
AU - Fiorini, Giulia
AU - Garre, Ana
AU - Garrido, Jesús
AU - F Pérez, Cristina
AU - Puig, Ignasi
AU - Heluwaert, Frederic
AU - Megraud, Francis
AU - O'Morain, Colm
AU - Gisbert, Javier P.
PY - 2021
Y1 - 2021
N2 - Objective The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. Results 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Conclusion Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.
AB - Objective The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. Results 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Conclusion Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.
KW - Adult
KW - Aged
KW - Anti-Bacterial Agents
KW - Drug Therapy, Combination
KW - Europe
KW - Female
KW - Helicobacter Infections
KW - Helicobacter pylori
KW - Humans
KW - Male
KW - Middle Aged
KW - Practice Patterns, Physicians'
KW - Prospective Studies
KW - Proton Pump Inhibitors
KW - Registries
KW - helicobacter pylori
KW - helicobacter pylori - treatment
KW - Adult
KW - Aged
KW - Anti-Bacterial Agents
KW - Drug Therapy, Combination
KW - Europe
KW - Female
KW - Helicobacter Infections
KW - Helicobacter pylori
KW - Humans
KW - Male
KW - Middle Aged
KW - Practice Patterns, Physicians'
KW - Prospective Studies
KW - Proton Pump Inhibitors
KW - Registries
KW - helicobacter pylori
KW - helicobacter pylori - treatment
UR - http://hdl.handle.net/10807/204831
U2 - 10.1136/gutjnl-2020-321372
DO - 10.1136/gutjnl-2020-321372
M3 - Article
SN - 0017-5749
VL - 70
SP - 40
EP - 54
JO - Gut
JF - Gut
ER -